A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab.
Respir Med Case Rep
; 47: 101968, 2024.
Article
em En
| MEDLINE
| ID: mdl-38274702
ABSTRACT
Dupilumab inhibits interleukin-4Rα and suppresses type 2 inflammation. Careful administration of dupilumab is required because it increases the blood eosinophil count secondary to a decrease in local eosinophil counts, sometimes resulting in eosinophilic complications. We herein report a case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab. A 54-year-old man with a history of eosinophilic pneumonia presented to our hospital with symptoms of cough, fever, and phlegm production six months after beginning dupilumab administration for recurrent chronic rhinosinusitis. When using dupilumab, it is essential to carefully monitor patients' eosinophil trends and pulmonary symptoms.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
4_TD
Base de dados:
MEDLINE
Idioma:
En
Revista:
Respir Med Case Rep
Ano de publicação:
2024
Tipo de documento:
Article